Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Halozyme (HALO)

Halozyme names David Ramsay interim CFO effective March 23, 2026

Neutral Impact 4 of 5 leadership Written later

Halozyme Therapeutics appointed David Ramsay as interim Chief Financial Officer, effective March 23, 2026, while it continues its search for a permanent CFO. Ramsay previously served as the company's CFO from 2003 to 2009 and from 2013 to 2015, and the filing describes his pay and equity grants for the interim role.

Key points

  • Ramsay will receive a monthly salary of $50,000 as interim CFO.
  • He will receive 10,000 restricted stock units vesting June 30, 2026, if he remains employed through that date.
  • If he is still interim CFO on July 1, 2026, he will receive an additional 2,500 RSUs.
  • The company has engaged an executive search firm for a permanent CFO, and Ramsay will serve until one is appointed.

The filing

CompanyHalozyme (HALO)
Form8-K, current report
Filed with the SECMar 12, 2026, 8:32 AM ET
Accession number0001159036-26-000035

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.